• Je něco špatně v tomto záznamu ?

Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy

KE. Aaltonen, V. Novosadová, PO. Bendahl, C. Graffman, AM. Larsson, L. Rydén,

. 2017 ; 8 (28) : 45544-45565.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18025034

Resistance to systemic therapy is a major problem in metastatic breast cancer (MBC) that can be explained by initial tumor heterogeneity as well as by evolutionary changes during therapy and tumor progression. Circulating tumor cells (CTCs) detected in a liquid biopsy can be sampled and characterized repeatedly during therapy in order to monitor treatment response and disease progression.Our aim was to investigate how CTC derived gene expression of treatment predictive markers (ESR1/HER2) and other cancer associated markers changed in patient blood samples during six months of first-line systemic treatment for MBC. CTCs from 36 patients were enriched using CellSearch (Janssen Diagnostics) and AdnaTest (QIAGEN) before gene expression analysis was performed with a customized gene panel (TATAA Biocenter).Our results show that antibodies against HER2 and EGFR were valuable to isolate CTCs unidentified by CellSearch and possibly lacking EpCAM expression. Evaluation of patients with clinically different breast cancer subgroups demonstrated that gene expression of treatment predictive markers changed over time. This change was especially prominent for HER2 expression.In conclusion, we found that changed gene expression during first-line systemic therapy for MBC could be a possible explanation for treatment resistance. Characterization of CTCs at several time-points during therapy could be informative for treatment selection.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18025034
003      
CZ-PrNML
005      
20180710092822.0
007      
ta
008      
180709s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.18632/oncotarget.17271 $2 doi
035    __
$a (PubMed)28489591
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Aaltonen, Kristina E $u Department of Clinical Sciences Lund, Division of Oncology and Pathology, Lund University, Lund, Sweden.
245    10
$a Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy / $c KE. Aaltonen, V. Novosadová, PO. Bendahl, C. Graffman, AM. Larsson, L. Rydén,
520    9_
$a Resistance to systemic therapy is a major problem in metastatic breast cancer (MBC) that can be explained by initial tumor heterogeneity as well as by evolutionary changes during therapy and tumor progression. Circulating tumor cells (CTCs) detected in a liquid biopsy can be sampled and characterized repeatedly during therapy in order to monitor treatment response and disease progression.Our aim was to investigate how CTC derived gene expression of treatment predictive markers (ESR1/HER2) and other cancer associated markers changed in patient blood samples during six months of first-line systemic treatment for MBC. CTCs from 36 patients were enriched using CellSearch (Janssen Diagnostics) and AdnaTest (QIAGEN) before gene expression analysis was performed with a customized gene panel (TATAA Biocenter).Our results show that antibodies against HER2 and EGFR were valuable to isolate CTCs unidentified by CellSearch and possibly lacking EpCAM expression. Evaluation of patients with clinically different breast cancer subgroups demonstrated that gene expression of treatment predictive markers changed over time. This change was especially prominent for HER2 expression.In conclusion, we found that changed gene expression during first-line systemic therapy for MBC could be a possible explanation for treatment resistance. Characterization of CTCs at several time-points during therapy could be informative for treatment selection.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    12
$a nádorové biomarkery $7 D014408
650    _2
$a nádory prsu $x genetika $x patologie $x terapie $7 D001943
650    _2
$a progrese nemoci $7 D018450
650    _2
$a chemorezistence $7 D019008
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a stanovení celkové genové exprese $7 D020869
650    12
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a lidé středního věku $7 D008875
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a staging nádorů $7 D009367
650    _2
$a nádorové cirkulující buňky $x metabolismus $x patologie $7 D009360
650    _2
$a receptor erbB-2 $x genetika $7 D018719
650    _2
$a receptory pro estrogeny $x genetika $7 D011960
650    _2
$a transkriptom $7 D059467
655    _2
$a časopisecké články $7 D016428
700    1_
$a Novosadová, Vendula $u Institute of Biotechnology, BIOCEV Centre, Czech Academy of Sciences, Vestec u Prahy, Czech Republic.
700    1_
$a Bendahl, Pär-Ola $u Department of Clinical Sciences Lund, Division of Oncology and Pathology, Lund University, Lund, Sweden.
700    1_
$a Graffman, Cecilia $u Skåne Department of Oncology, Skåne University Hospital, Lund, Sweden.
700    1_
$a Larsson, Anna-Maria $u Skåne Department of Oncology, Skåne University Hospital, Lund, Sweden. Department of Translational Cancer Research, Lund University, Lund, Sweden.
700    1_
$a Rydén, Lisa $u Department of Clinical Sciences Lund, Division of Surgery, Lund University, Lund, Sweden. Department of Surgery, Skåne University Hospital, Malmö, Sweden.
773    0_
$w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 8, č. 28 (2017), s. 45544-45565
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28489591 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180710093112 $b ABA008
999    __
$a ok $b bmc $g 1317165 $s 1021955
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 8 $c 28 $d 45544-45565 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

    Možnosti archivace